Tests dapagliflozin for kidney function in advanced chronic kidney disease
Tests dapagliflozin against placebo in adults with advanced chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 3
Where in Egypt
- Ain Shams University HospitalsCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT06982079
- Record updated
- 21 May 2025
- Original description
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. The main questions it aims to answer are:Read full original descriptionShow less
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. The main questions it aims to answer are:
1. Does dapagliflozin reduce the rate of decline in kidney function or progression to end-stage kidney disease in adults with advanced CKD? 2. Does dapagliflozin reduce the risk of death from cardiovascular or renal causes in patients with advanced CKD?
Researchers will compare dapagliflozin to a placebo to see if dapagliflozin improves kidney and cardiovascular outcomes in this high-risk population.
Inclusion: Adult patients aged eighteen or older; Patients with advanced chronic kidney disease (i.e., eGFR < 20 mL/min/1.73m2)not on dialysis.
Exclusion: Patients on SGLT2 inhibitors; Autosomal dominant polycystic kidney disease (ADPKD); Type 1 diabetes mellitus; History of ketoacidosis in the last 3 months; Known hypersensitivity to SGLT2 inhibitors; Known hepatic impairment; Pregnant or breastfeeding females.